07:00 , Jun 14, 2012 |  BC Innovations  |  Tools & Techniques

Vaccines revisited

A team from Oregon Health & Science University and Najít Technologies Inc. has shown that hydrogen peroxide could be a better way to inactivate viral vaccines than conventional methods such as formaldehyde and b-propiolactone. 1...
07:00 , Aug 4, 2008 |  BioCentury  |  Finance

Acambis chronicles

Acambis chronicles...
07:00 , Sep 18, 2006 |  BC Week In Review  |  Company News

Acambis, Novartis, Centers for Disease Control and Prevention infectious news

ACM said the CDC agreed to purchase an additional 10 million doses of the company's ACAM2000 smallpox vaccine under an existing supply contract. ACM said the new order is worth about $30 million. Under the...
07:00 , Sep 18, 2006 |  BioCentury  |  Finance

Ebb & Flow

When...
00:25 , Sep 14, 2006 |  BC Extra  |  Company News

Acambis up on ACAM2000, Arilvax news

Acambis (LSE:ACM; ACAM) was up 8p to 144p on Wednesday after announcing a new order for ACAM2000 smallpox vaccine and the settlement of an Arlivax dispute. The U.S. government agreed to purchase an additional 10...
08:00 , Mar 14, 2005 |  BioCentury  |  Finance

Ebb & Flow

TransForm Pharmaceuticals...
02:30 , Mar 9, 2005 |  BC Extra  |  Financial News

Acambis reports earnings

Acambis (LSE:ACM; ACAM) reported fourth quarter and full year 2004 earnings and hinted that in 2005, it may sacrifice profitability in favor of R&D investment. The company also said that a BLA for its Arilvax...
07:00 , Sep 27, 2004 |  BioCentury  |  Strategy

Acambis pipeline

Acambis pipeline...
07:00 , Sep 27, 2004 |  BioCentury  |  Strategy

Acambis: Life after the CDC

The trouble with government contracts is that they are binary: you either win them or you don't. When a proposed order worth millions is not taken up, the ramifications for a company can underline the...
08:00 , Feb 23, 2004 |  BC Week In Review  |  Clinical News

Arilvax live attenuated yellow fever vaccine regulatory update

ACM temporarily withdrew a BLA for Arilvax vaccine to prevent yellow fever, and expects to resubmit the BLA in the first half of 2005. ACM said that CHIR subsidiary Chiron Vaccines is planning to upgrade...